Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced Cancer
Open Access
- 14 February 2012
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 17 (3), 419-427
- https://doi.org/10.1634/theoncologist.2011-0323
Abstract
Background.: Evidence-based treatment guidelines recommend low molecular weight heparin (LMWH) monotherapy for cancer-associated venous thromboembolism (VTE). This analysis assessed the first-line treatment strategies for VTE in patients with advanced solid tumors. Methods.: Using administrative data from advanced lung, prostate, colon, or breast cancer patients diagnosed between January 2000 and December 2007 at four HMOs with integrated delivery systems, patients with an inpatient or outpatient VTE diagnosed within 2 years after cancer diagnosis and an outpatient purchase of warfarin, LMWH, and/or fondaparinux anticoagulant within 7 days of the VTE diagnosis were identified. First-line outpatient VTE pharmacological treatment and factors independently associated with receipt/non-receipt of LMWH monotherapy were assessed. Results.: Overall, 25% of the 1,089 eligible patients received LMWH monotherapy as primary VTE treatment. The percentage increased steadily over time from 18% among patients diagnosed in 2000 to 31% among those diagnosed in 2007. Factors associated with LMWH monotherapy included VTE diagnosis year, chemotherapy within 60 days prior to VTE diagnosis, history of VTE prior to cancer diagnosis, and invasive surgery in the 90 days following VTE diagnosis. Colorectal and prostate cancer patients versus lung cancer patients and stage III versus stage IV patients were less likely to be treated with LMWH monotherapy. Conclusions.: Adoption of LMWH monotherapy as initial treatment for cancer-associated VTE was low but increased steadily over the study period. Future studies should explore reasons underlying the underutilization of this preferred evidence-based treatment as well as the comparative effectiveness of LMWH versus warfarin-based anticoagulation in real-world cancer patients with VTE.Keywords
Funding Information
- National Cancer Institute (NCI 5U19CA079689, U19CA79689)
This publication has 25 references indexed in Scilit:
- Effect of a Centralized Clinical Pharmacy Anticoagulation Service on the Outcomes of Anticoagulation TherapySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2005
- Antithrombotic Therapy for Venous Thromboembolic DiseaseSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2004
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?Journal of Clinical Oncology, 2003
- Diagnosis of venous thromboembolic disease in cancer patients.2003
- Low-Molecular-Weight Heparin and CancerSeminars in Thrombosis and Hemostasis, 2000
- The Thrombophilic State Induced by Therapeutic Agents in the Cancer PatientSeminars in Thrombosis and Hemostasis, 1999
- Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous ThromboembolismArchives of Internal Medicine, 1999
- The Long-Term Clinical Course of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 1996
- Incidence of venous thromboembolism verified by necropsy over 30 years.BMJ, 1991